Document:

Exhibit 10.7

 

AMENDMENT
NO. 1

TO

FUTURE ADVANCE PROMISSORY NOTE

 

This AMENDMENT NO.
1 (the “Amendment”) dated May 15, 2017, is to that certain FUTURE ADVANCE PROMISSORY NOTE (as amended, modified
or supplemented in accordance therewith, the “Note”) which was effective as of March 15, 2015, by Avenue Therapeutics,
Inc. a Delaware corporation (the “Company”), in favor of Fortress Biotech, Inc., a Delaware corporation (the
“Manager” and individually a “Party” or collectively the “Parties”).

 

WHEREAS, contingent
upon the Company’s launch of an initial public offering, the Parties wish to amend the Note to alter the interest rate payable
by Avenue under the Agreement.

 

NOW, THEREFORE, in
consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties hereto agree as follows:

 

1.                 
Amendment to Section 1. Section 1 of the Note shall be deleted in its entirety and substituted with the following:

 

“1.Principal and Interest.
Avenue Therapeutics, Inc. (the “Company”), for value received, pursuant to this Future Advance Promissory
Note (the “Note”) hereby promises to pay to the order of Fortress Biotech, Inc. (“Fortress”),
in lawful money of the United States of America, the principal amount as may be advanced from time to time by Fortress as shown
on Exhibit A attached hereto, with interest from the date of each advance at 2% per annum on the unpaid balance until paid.
Interest shall be accrued and, following a Financing (as defined below), payable quarterly on the day following each calendar quarter.
Following a Financing, such principal and accrued interest shall be due and payable on demand. All unpaid principal and interest
on this Note may be prepaid at any time without penalty. For purposes of this Note, a “Financing” shall
mean an equity, debt or royalty financing or series of related equity, debt or royalty financings by the Company resulting in the
Company receiving cash proceeds from unaffiliated third parties.”

 

2.                 
Condition Precedent to Effectiveness of Amendment. This Amendment shall have no force or effect until the Company’s
launch of an initial public offering.

 

3.                 
Remainder of Agreement. Except as expressly set forth in this Amendment, the provisions of the Note will remain in
full force and effect, in their entirety, in accordance with their terms.

 

4.                 
Miscellaneous. This Amendment shall be governed, construed, and interpreted in accordance with the laws of the State
of New York, without giving effect to conflicts of laws principles of any jurisdiction. The Parties agree that this Amendment may
only be modified in a signed writing executed by each of the parties hereto. This Amendment shall be binding upon and shall inure
to the benefit of the parties hereto and their respective heirs, successors and assigns.

 

     

     

    

 

This Amendment may be executed in separate
counterparts, each of which is deemed to be an original and all of which taken together constitute one agreement. Facsimile or
PDF reproductions of original signatures will be deemed binding for the purpose of the execution of this Amendment.

 

 

* * * * * *

 

 

 

 

     

     

    

 

IN WITNESS WHEREOF,
the Parties hereto have executed this Amendment as of the date first written above.

 

	 	AVENUE THERAPEUTICS, INC.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Lucy Lu	 
	 	Name:	Lucy Lu	 
	 	Title:	Interim Chief Executive Officer	 
	 	 	 	 
	 	 	 	 
	 	FORTRESS BIOTECH, INC.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Lindsay A. Rosenwald	 
	 	Name:	Lindsay A. Rosenwald	 
	 	Title:	Chief Executive OfficerExhibit 10.9

 

AMENDMENT
NO. 1

 

TO

 

MANAGEMENT SERVICES AGREEMENT

 

This AMENDMENT NO.
1 (the “Amendment”) dated May 15, 2017, is to that certain MANAGEMENT SERVICES AGREEMENT (the “Agreement”)
which was effective as of February 17, 2015, by and between Avenue Therapeutics, Inc. a Delaware corporation (the “Company”),
and Fortress Biotech, Inc., a Delaware corporation (the “Manager” and individually a “Party”
or collectively the “Parties”).

 

WHEREAS, on the terms
and subject to the conditions contained in the Agreement, the Company desires to obtain certain management, advisory and consulting
services from the Manager, and the Manager has agreed to perform such management, advisory and consulting services;

 

WHEREAS, contingent
upon the Company’s launch of an initial public offering, the Parties wish to amend the Agreement to alter the structure of
the compensation the Company pays to the Manager for the services provided under the Agreement; and

 

NOW, THEREFORE, in
consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties hereto agree as follows:

 

1.                 
Amendment to Section 3. Section 3 of the Agreement shall be deleted in its entirety and substituted with the following:

 

3.       Compensation.

 

3.1       In
consideration of the management, consulting and financial services to be rendered, the Company will pay to the Manager an annual
base management and consulting fee, in the Company’s sole discretion, either: (i) in cash in the aggregate amount of five
hundred thousand dollars ($500,000); (ii) shares of the common stock of the Company, par value $0.0001 per share (the “Stock”)
with a Fair Market Value (defined below) of five hundred thousand dollars ($500,000), (either (i) or (ii), the “Annual
Consulting Fee”); provided, however, that, notwithstanding the foregoing or any other provision hereof, following
the Company’s launch of an initial public offering, the Annual Consulting Fee shall be payable solely in cash, The Annual
Consulting Fee shall be payable in advance in equal quarterly installments on the first business day of each calendar quarter in
each year, provided, that such Annual Consulting Fee shall be increased to $1,000,000 for each calendar year in which the
Company has Net Assets in excess of $100,000,000 at the beginning of the calendar year. For purposes of this Agreement, “Net
Assets” shall mean the difference between total assets on the one hand and current liabilities and non-capitalized long-term
liabilities on the other hand.

 

     

     

    

 

“Fair Market Value” on
any date, means (i) if the Stock is listed on an stock exchange, the closing sales price on such exchange on such date or, in the
absence of reported sales on such date, the closing sales price on the immediately preceding date on which sales were reported,
or (ii) if the Stock is not listed on an exchange, the mean between the bid and offered prices as quoted by the applicable interdealer
quotation system for such date, provided that if the Stock is not quoted on an interdealer quotation system or it is determined
that the fair market value is not properly reflected by such quotations, Fair Market Value will be determined by such other method
as the Board of Directors of the Company determines in good faith to be reasonable.

 

The fees due to Manager pursuant to
this Section 3.1 shall be referred to as the “Management Fee.” Notwithstanding the foregoing, the first
Annual Consulting Fee payment shall be made on the first business day of the calendar quarter immediately following the completion
of the first equity financing for the Company that is in excess of $10,000,000 in gross proceeds. The first payment shall include
all amounts in arrears from the date hereof through such payment as well as the amounts in advance for such first quarterly payment.

 

3.2       Any
payment pursuant to this Section 3 shall be made in cash by wire transfer(s) of immediately available funds to or among
one or more accounts as designated from time-to-time by the Manager to the Company in writing.

 

2.                 
Condition Precedent to Effectiveness of Amendment. This Amendment shall have no force or effect until the Company’s
launch of an initial public offering.

 

3.                 
Remainder of Agreement. Except as expressly set forth in this Amendment, the provisions of the Agreement will remain
in full force and effect, in their entirety, in accordance with their terms.

 

4.                 
Miscellaneous. This Amendment shall be governed, construed, and interpreted in accordance with the laws of the State
of New York, without giving effect to conflicts of laws principles of any jurisdiction. The Parties agree that this Amendment may
only be modified in a signed writing executed by each of the parties hereto. This Amendment shall be binding upon and shall inure
to the benefit of the parties hereto and their respective heirs, successors and assigns. This Amendment may be executed in separate
counterparts, each of which is deemed to be an original and all of which taken together constitute one agreement. Facsimile or
PDF reproductions of original signatures will be deemed binding for the purpose of the execution of this Amendment.

 

 

 

* * * * * *

 

 

     

     

    

 

IN WITNESS WHEREOF,
the Parties hereto have executed this Amendment as of the date first written above.

 

	 	AVENUE THERAPEUTICS, INC.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Lucy Lu	 
	 	Name:	Lucy Lu	 
	 	Title:	Interim Chief Executive Officer	 
	 	 	 	 
	 	 	 	 
	 	FORTRESS BIOTECH, INC.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Lindsay A. Rosenwald	 
	 	Name:	Lindsay A. Rosenwald	 
	 	Title:	Chief Executive Officerebixexh1012creditamendme

   94953224_3 AMENDMENT NO. 3 TO CREDIT AGREEMENT AND WAIVER  This AMENDMENT NO. 3 TO CREDIT AGREEMENT AND WAIVER (this “Amendment”), dated as of October 19, 2017, is entered into by and among EBIX, INC., a Delaware corporation (the “Borrower”), certain subsidiaries of the Borrower party hereto as guarantors (the “Guarantors” and collectively with the Borrower, the “Credit Parties”) under the Credit Agreement (defined below), each Lender (as defined below) that is a party hereto and REGIONS BANK, as administrative agent (in such capacity, the “Administrative Agent”) and collateral agent. RECITALS WHEREAS, the Borrower, the Administrative Agent and certain banks and other financial institutions (the “Lenders”) are parties to that certain Credit Agreement, dated as of August 5, 2014 (as amended hereby, as amended by that certain Amendment No. 1 to Credit Agreement and Waiver dated as of February 3, 2015, as further amended by that certain Amendment No. 2 to Credit Agreement dated as of June 17, 2016, and as further amended, restated, extended, supplemented or otherwise modified from time to time, the “Credit Agreement”), pursuant to which the Lenders have extended a revolving credit facility and term loan facility to the Borrower;  WHEREAS, the Borrower and/or certain of its Subsidiaries have made one or more Restricted Payments during the period from October 1, 2016 through September 30, 2017 in excess of the amount permitted under the Credit Agreement, and as a result of which one or more Events of Default has occurred and is continuing under the Credit Agreement (the “RP Events of Default”);  WHEREAS, certain other Events of Default have occurred and are continuing directly and solely as a result of the occurrence of the RP Events of Default, including as a result of one or more Credit Parties representing and warranting to the absence of a Default or an Event of Default during the pendency of the RP Events of Default (to the extent arising directly and solely from the occurrence of the RP Events of Default, and not from any unrelated action or inaction by the Borrower, any other Credit Party or any of their Subsidiaries, the “Directly Ensuing Events of Default”);   WHEREAS, the Borrower has requested that the Lenders agree (a) to waive the RP Events of Default and the Directly Ensuing Events of Default and (b) to amend certain provisions of the Credit Agreement, as more particularly set forth below, and the Lenders party hereto are willing to effect such waiver and such amendments, as provided in, and on the terms and conditions contained in, this Amendment;  NOW, THEREFORE, for valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto hereby agree as follows: 1. Defined Terms.  Unless otherwise defined herein, capitalized terms used herein shall have the meanings, if any, assigned to such terms in the Credit Agreement, as amended by this Amendment.   2. Amendments to Credit Agreement.  Subject to the terms and conditions hereof and with effect from and after the Third Amendment Effective Date (defined below), the Credit Agreement is hereby amended by:  (a) replacing the definition of “Permitted Restricted Payment Limit” in its entirety as follows: 

 

 2 94953224_3 “ ‘Permitted Restricted Payment Limit’ means, with respect to any Fiscal Year, an amount equal to the sum of (a) $20,000,000 plus (b) amounts available to, but not utilized by, the Borrower pursuant to clause (a) in the Fiscal Year in which the Second Amendment Effective Date occurs and each ensuing Fiscal Year; provided that if the Consolidated Net Leverage Ratio, determined on a pro forma basis (as provided in Section 1.3) as of the date of any Restricted Payment, is less than 2.25 to 1.00, the amount of such Restricted Payment shall be deemed to be within the Permitted Restricted Payment Limit but not constitute usage of the dollar amounts in clauses (a) and (b).”  (b) adding the following proviso to the end of Section 8.3 of the Credit Agreement: “; provided that notwithstanding the foregoing, during the period from October 1, 2017 through and including December 31, 2017, the foregoing clause (c) shall be limited solely to the payment of dividends (and not any other distribution, including any repurchase of Equity Interests)  in an aggregate amount not to exceed $2,750,000 (and for the avoidance of doubt, the requirements of clauses (a) and (b) of the definition of Permitted Restricted Payment shall be required to be satisfied in connection with any Restricted Payment made during such period pursuant to the foregoing clause (c))”. The parties hereto agree and understand that the amendments provided by this Section 2 shall be deemed effective once all of the conditions in Section 5 of this Amendment have been satisfied (such date, the “Third Amendment Effective Date”).  3. Waiver of Defaults.  In reliance upon the representations, warranties and covenants of the Borrower and each other Credit Party contained in this Amendment, and subject to the effectiveness and the terms and conditions of this Amendment, including, without limitation, those set forth in Section 5 hereof, as of the Third Amendment Effective Date, the undersigned Lenders hereby waive the RP Events of Default and the Directly Ensuing Events of Default; provided that in no event shall any Default or Event of Default other than the RP Events of Default and the Directly Ensuing Events of Default (including any Default or Event of Default arising as a result of any action or inaction after the Third Amendment Effective Date) be waived. 4. Representations and Warranties.  The Borrower and each of the other Credit Parties, by its execution of this Amendment, hereby represents and warrants to the Administrative Agent and the Lenders as follows: (a) the execution, delivery and performance by each Credit Party of this Amendment have been duly authorized by all necessary corporate or other organizational action and do not and will not (i) violate in any material respect the terms of any of the Credit Parties’ Organizational Documents; (ii) except as could not reasonably be expected to have a Material Adverse Effect, conflict with, result in a breach of or constitute (with due notice or lapse of time or both) a default under any other Contractual Obligations of any Credit Party, (iii) result in or require the creation of any Lien upon any of the properties or assets of any Credit Party (other than Liens created under any of the Credit Documents in favor of the Collateral Agent for the benefit of the holders of the Obligations), or (iv) require any approval of stockholders, members or partners or any approval or consent of any Person under any material Contractual Obligation of any Credit Party; (b) this Amendment has been duly executed and delivered by each Credit Party, and constitutes a legal, valid and binding obligation of each Credit Party, enforceable against such Credit Party in accordance with its terms, except as may be limited by Debtor Relief Laws or by equitable principles relating to enforceability; 

 

 3 94953224_3 (c) the representations and warranties of each Credit Party contained in Section 6 of the Credit Agreement and in each other Credit Document are true and correct in all material respects on and as of the Third Amendment Effective Date  and after giving effect to this Amendment, except to the extent that such representations and warranties specifically relate to an earlier date, in which case they shall be true and correct in all material respects as of such earlier date, and except that for purposes of this clause (c), the representations and warranties contained in Sections 6.7(a) and (b) of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant to Sections 7.1(b) and (a) of the Credit Agreement, respectively; and (d) after the effectiveness of this Amendment (including the waivers set forth in Section 3 above) on the Third Amendment Effective Date, no Default has occurred and is continuing. 5. Effectiveness; Conditions Precedent.  The effectiveness of this Amendment and the amendments to the Credit Agreement herein provided are subject to the satisfaction of the following conditions precedent: (a) the Administrative Agent shall have received, in form and substance reasonably acceptable to the Administrative Agent, counterparts of this Amendment, duly executed by each Credit Party, the Administrative Agent, and the Required Lenders; (b) each of the representations and warranties set forth in Section 4 above is true and correct in all material respects (or, with respect to any such representation or warranty modified by a materiality or Material Adverse Effect standard, in all respects (taking into account such materiality or Material Adverse Effect standard));  (c) after giving effect to this Amendment (including the waivers set forth in Section 3 above), as of the Third Amendment Effective Date, no Default or Event of Default shall have occurred and be continuing; and (d) all fees and expenses payable to the Administrative Agent (including the fees and expenses of counsel to the Administrative Agent to the extent invoiced prior to the date hereof) shall have been paid in full (without prejudice to final settling of accounts for such fees and expenses). 6. Reaffirmation.  Each Credit Party (a) acknowledges and consents to all of the terms and conditions of this Amendment, (b) affirms all of its obligations under the Credit Documents, as amended hereby, and (c) agrees that this Amendment and all documents executed in connection herewith do not operate to reduce or discharge any Credit Party’s obligations under the Credit Documents. 7. Miscellaneous. (a) Nothing in this Amendment is intended (or shall be construed) to constitute the consent of the Administrative Agent or any Lender to any other transaction or the waiver by the Administrative Agent or any Lender of any Default or Event of Default, except as expressly provided herein.   (b) Except as herein expressly amended, all terms, covenants and provisions of the Credit Agreement and each other Credit Document are and shall remain in full force and effect.  All references in any Credit Document to the “Credit Agreement” or “this Agreement” (or similar terms intended to reference the Credit Agreement) shall henceforth refer to the Credit Agreement as amended by this Amendment.  This Amendment shall be deemed incorporated into, and a part of, the Credit Agreement. 

 

 4 94953224_3 (c) This Amendment shall be binding upon and inure to the benefit of the parties hereto, each other Lender and each other Credit Party, and their respective successors and assigns. (d) THIS AMENDMENT IS SUBJECT TO THE PROVISIONS OF SECTIONS 11.13 AND 11.14 OF THE CREDIT AGREEMENT RELATING TO GOVERNING LAW, VENUE AND WAIVER OF RIGHT TO TRIAL BY JURY, THE PROVISIONS OF WHICH ARE BY THIS REFERENCE INCORPORATED HEREIN IN FULL. (e) This Amendment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.  This Amendment and the other Credit Documents constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof.  This Amendment shall become effective upon satisfaction of the conditions set forth in Section 5 hereof.  Delivery of an executed counterpart of a signature page of this Amendment by telecopy or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Amendment.  This Amendment may not be amended except in accordance with the provisions of Section 11.4 of the Credit Agreement. (f) If any provision of this Amendment or the other Credit Documents is held to be illegal, invalid or unenforceable, (i) the legality, validity and enforceability of the remaining provisions of this Amendment and the other Credit Documents shall not be affected or impaired thereby and (ii) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions.  The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.   (g) The Borrower agrees to pay, in accordance with and subject to the limitations in Section 11.2 of the Credit Agreement, all reasonable and documented out-of-pocket expenses incurred by the Administrative Agent and its Affiliates in connection with the preparation, execution, delivery, administration of this Amendment and the other instruments and documents to be delivered hereunder. (h) This Amendment shall constitute a “Credit Document” under and as defined in the Credit Agreement. [Signature Pages Follow.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]